ET-53 IPILIMUMAB FOR RECURRENT GLIOBLASTOMA (GBM)

Available treatments for recurrent glioblastoma (GBM) are inadequate, and median survival is approximately 6 months. Ipilimumab (ipi) is an immune modulator that inhibits CTLA-4 and is active in refractory melanoma, including brain metastases. We retrospectively reviewed records of patients treated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Schaff, Lauren R., Lassman, Andrew B., Goldlust, Samuel A., Cloughesy, Timothy, Singer, Samuel, Schwartz, Gary K., Iwamoto, Fabio M.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218149/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou255.50
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados